Curium Drug Patent Portfolio
Curium owns 3 orange book drugs protected by 8 US patents Given below is the list of Curium's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12102696 | Radiolabeling and formulation for scale up of 64Cu-DOTATATE | 03 Sep, 2041 | Active |
| US10159759 | Pet tracer for imaging of neuroendocrine tumors | 23 Aug, 2032 | Active |
| US10383961 | PET tracer for imaging of neuroendocrine tumors | 23 Aug, 2032 | Active |
| US11160888 | PET tracer for imaging of neuroendocrine tumors | 23 Aug, 2032 | Active |
| US6123916 | Therapeutic use of somatostatin peptides | 26 Sep, 2017 | Expired |
| US5776894 | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors | 07 Jul, 2015 | Expired |
| US5753627 | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis | 19 May, 2015 | Expired |
| US5573748 | Radiolabeled technetium chelates for use in renal function determinations | 12 Nov, 2013 | Expired |
Latest Legal Activities on Curium's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Curium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Requirement for information sent under 37 CFR 1.750 | 11 Jun, 2024 | US10383961 |
| Notice of Final Determination -Eligible | 11 Jun, 2024 | US10383961 |
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US10383961 |
| transaction for FDA Determination of Regulatory Review Period | 10 May, 2023 | US10383961 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US10383961 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Feb, 2023 | US10383961 |
| Second letter to regulating agency to determine regulatory review period | 17 Jun, 2022 | US10383961 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Jun, 2022 | US10159759 |
| Letter from FDA or Dept of Agriculture re PTE application | 14 Jun, 2022 | US10383961 |
| Initial letter Re: PTE Application to regulating agency | 13 Apr, 2022 | US10383961 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Nov, 2021 | US11160888 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Nov, 2021 | US11160888 |
| Sequence Moved to Public Database | 02 Nov, 2021 | US11160888 |
|
Email Notification
Critical
| 14 Oct, 2021 | US11160888 |
|
Issue Notification Mailed
Critical
| 13 Oct, 2021 | US11160888 |
Curium's Family Patents
Curium Drug List
Given below is the complete list of Curium's drugs and the patents protecting them.
1. Detectnet
Detectnet is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12102696 | Radiolabeling and formulation for scale up of 64Cu-DOTATATE |
03 Sep, 2041
(16 years from now)
| Active |
| US10159759 | Pet tracer for imaging of neuroendocrine tumors |
23 Aug, 2032
(7 years from now)
| Active |
| US10383961 | PET tracer for imaging of neuroendocrine tumors |
23 Aug, 2032
(7 years from now)
| Active |
| US11160888 | PET tracer for imaging of neuroendocrine tumors |
23 Aug, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Detectnet's drug page
2. Octreoscan
Octreoscan is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6123916 | Therapeutic use of somatostatin peptides |
26 Sep, 2017
(7 years ago)
| Expired |
| US5776894 | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors |
07 Jul, 2015
(9 years ago)
| Expired |
| US5753627 | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
19 May, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Octreoscan's drug page
3. Technescan Mag3
Technescan Mag3 is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5573748 | Radiolabeled technetium chelates for use in renal function determinations |
12 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Technescan Mag3's drug page